Humana Inc. (NYSE:HUM) Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC lessened its position in Humana Inc. (NYSE:HUM) by 68.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,172 shares of the insurance provider’s stock after selling 78,037 shares during the period. Intech Investment Management LLC’s holdings in Humana were worth $9,177,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Pzena Investment Management LLC boosted its position in shares of Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after buying an additional 1,103,132 shares during the period. FMR LLC boosted its position in Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after acquiring an additional 643,291 shares during the period. Retirement Systems of Alabama grew its stake in shares of Humana by 735.9% in the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after purchasing an additional 192,801 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new position in shares of Humana during the third quarter valued at $50,102,000. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Humana by 42.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 391,657 shares of the insurance provider’s stock valued at $124,053,000 after purchasing an additional 115,820 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.37% of the company’s stock.

Humana Stock Performance

Shares of HUM stock opened at $269.86 on Wednesday. The company has a market capitalization of $32.57 billion, a price-to-earnings ratio of 27.12, a P/E/G ratio of 2.05 and a beta of 0.57. The stock’s fifty day simple moving average is $271.45 and its 200-day simple moving average is $278.29. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46.

Humana (NYSE:HUM) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.31%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $283.00 target price on shares of Humana in a research note on Wednesday, February 12th. Piper Sandler boosted their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. StockNews.com downgraded Humana from a “buy” rating to a “hold” rating in a research report on Tuesday. Barclays boosted their price objective on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Finally, Truist Financial raised their target price on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.